Cancer Research Cancer Health Disparities Conference 2009  AM No Date
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berry, S. E.
Right arrow Articles by Kinsella, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, S. E.
Right arrow Articles by Kinsella, T. J.
[Cancer Research 63, 5490-5495, September 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Role of MutS{alpha} in the Recognition of Iododeoxyuridine in DNA1

Suzanne E. Berry, Tamalette Loh, Tao Yan and Timothy J. Kinsella2

Department of Radiation Oncology, Case Western Reserve University, School of Medicine and University Hospitals of Cleveland/Ireland Cancer Center, Cleveland, Ohio 44106

We have previously demonstrated that both the MLH1 and MSH2 status impact the DNA levels of the halogenated thymidine (dThd) analogues iododeoxyuridine (IdUrd) and bromodeoxyuridine (BrdUrd), and thereby radiosensitization induced by these analogues, indirectly implicating both mismatch repair (MMR) proteins in the removal of these bases from DNA. More recent data from our group demonstrate that base excision repair (BER) also impacts IdUrd-DNA levels, supporting a role for the BER pathway in IdUrd removal as well. In this study, we have examined more direct interactions between the MSH2 protein and the processing of IdUrd incorporated in DNA. Our data demonstrate that the MutS{alpha} (MSH2/MSH6) complex binds specifically to DNA containing an IdUrd-G mismatch, using both purified human MutS{alpha} as well as nuclear extracts from Msh2-proficient and-deficient mouse cell lines. MutS{alpha} binding to a IdUrd-G is better recognized than a G-T mismatch in the same sequence context. In addition, MSH2 protein can be found colocalized with IdUrd-DNA using confocal microscopy in G1 synchronized cells after treatment with IdUrd. Consistent with our recent publication, coadministration of IdUrd and a chemical inhibitor of BER, methoxyamine (MX), also increases the extent of MSH2 nuclear colocalization with IdUrd. Furthermore, we show that the extent of MSH2 colocalization with IdUrd in G1-synchronized human tumor cells varies with MLH1 status, suggesting a role for the MLH1 protein in stabilizing the interaction between the MSH2 protein and DNA containing IdUrd. These data, both in vitro and in vivo, suggest direct involvement of MSH2 in processing IdUrd in DNA.




This article has been cited by other articles:


Home page
Cancer Res.Home page
E. Gurkan, J. E. Schupp, M. A. Aziz, T. J. Kinsella, and K. A. Loparo
Probabilistic Modeling of DNA Mismatch Repair Effects on Cell Cycle Dynamics and Iododeoxyuridine-DNA Incorporation
Cancer Res., November 15, 2007; 67(22): 10993 - 11000.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Yamane, J. E. Schupp, and T. J. Kinsella
BRCA1 Activates a G2-M Cell Cycle Checkpoint following 6-Thioguanine-Induced DNA Mismatch Damage
Cancer Res., July 1, 2007; 67(13): 6286 - 6292.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. P. Turner, S. Cortellino, J. E. Schupp, E. Caretti, T. Loh, T. J. Kinsella, and A. Bellacosa
The DNA N-Glycosylase MED1 Exhibits Preference for Halogenated Pyrimidines and Is Involved in the Cytotoxicity of 5-Iododeoxyuridine.
Cancer Res., August 1, 2006; 66(15): 7686 - 7693.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Yan, Y. Seo, J. E. Schupp, X. Zeng, A. B. Desai, and T. J. Kinsella
Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence.
Mol. Cancer Ther., April 1, 2006; 5(4): 893 - 902.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Seo, T. Yan, J. E. Schupp, K. Yamane, T. Radivoyevitch, and T. J. Kinsella
The Interaction between Two Radiosensitizers: 5-Iododeoxyuridine and Caffeine
Cancer Res., January 1, 2006; 66(1): 490 - 498.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
K. Dornfeld and M. Johnson
AP endonuclease deficiency results in extreme sensitivity to thymidine deprivation
Nucleic Acids Res., November 27, 2005; 33(20): 6644 - 6653.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Seo, T. Yan, J. E. Schupp, V. Colussi, K. L. Taylor, and T. J. Kinsella
Differential Radiosensitization in DNA Mismatch Repair-Proficient and -Deficient Human Colon Cancer Xenografts with 5-Iodo-2-pyrimidinone-2'-deoxyribose
Clin. Cancer Res., November 15, 2004; 10(22): 7520 - 7528.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.